BR112015023187A2 - inibidores de pirrolo[2,3 - b] piridina cdk9 kinase - Google Patents
inibidores de pirrolo[2,3 - b] piridina cdk9 kinaseInfo
- Publication number
- BR112015023187A2 BR112015023187A2 BR112015023187A BR112015023187A BR112015023187A2 BR 112015023187 A2 BR112015023187 A2 BR 112015023187A2 BR 112015023187 A BR112015023187 A BR 112015023187A BR 112015023187 A BR112015023187 A BR 112015023187A BR 112015023187 A2 BR112015023187 A2 BR 112015023187A2
- Authority
- BR
- Brazil
- Prior art keywords
- pyrrolo
- pyridine
- kinase inhibitors
- compounds
- cdk9 kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
resumo “inibidores de pirrolo[2,3 – b] piridina cdk9 kinase” são descritos compostos da formula (iia), em que r1, r2, r3a, r3b, r3c, r3d, r3e e r4 são definidos como no relatório descritivo e sais farmaceuticamente aceitáveis do mesmo. os compostos podem ser usados como agentes no tratamento de doenças, incluindo câncer. também são fornecidas composições farmacêuticas compreendendo um ou mais composto da formula (iia). fórmula (iia),
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN745DE2013 | 2013-03-14 | ||
US201361904842P | 2013-11-15 | 2013-11-15 | |
PCT/CN2014/000265 WO2014139328A1 (en) | 2013-03-14 | 2014-03-13 | Pyrrolo[2,3-b]pyridine cdk9 kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015023187A2 true BR112015023187A2 (pt) | 2017-07-18 |
Family
ID=54249678
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023356A BR112015023356A2 (pt) | 2013-03-14 | 2014-03-13 | inibidores de quinase pirrol[2,3-b]piridina cdk9 |
BR112015023187A BR112015023187A2 (pt) | 2013-03-14 | 2014-03-13 | inibidores de pirrolo[2,3 - b] piridina cdk9 kinase |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015023356A BR112015023356A2 (pt) | 2013-03-14 | 2014-03-13 | inibidores de quinase pirrol[2,3-b]piridina cdk9 |
Country Status (9)
Country | Link |
---|---|
US (1) | US9796708B2 (pt) |
EP (2) | EP2970278A4 (pt) |
JP (2) | JP2016514113A (pt) |
CN (2) | CN105324380A (pt) |
AR (1) | AR101528A1 (pt) |
AU (2) | AU2014234077A1 (pt) |
BR (2) | BR112015023356A2 (pt) |
CA (2) | CA2905530A1 (pt) |
MX (2) | MX2015012896A (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019057123A1 (zh) * | 2017-09-20 | 2019-03-28 | 杭州英创医药科技有限公司 | 作为ido抑制剂和/或ido-hdac双重抑制剂的多环化合物 |
CA3076714C (en) * | 2019-09-29 | 2021-06-15 | Mabplex International, Ltd. | Method for producing antibody-drug conjugate intermediate by addition of acid and use thereof |
MA57379B1 (fr) * | 2019-10-18 | 2024-02-29 | Lead Pharma Holding Bv | Modulateurs du recepteur alpha associe aux oestrogenes (err-alpha) |
CN116249701A (zh) * | 2020-10-12 | 2023-06-09 | 上海海雁医药科技有限公司 | 取代的二(吡啶-2-基)胺衍生物、其组合物及医药上的用途 |
WO2022135580A1 (zh) * | 2020-12-25 | 2022-06-30 | 南京明德新药研发有限公司 | 吡啶并吡咯类化合物的晶型、制备方法及其应用 |
CN112852874B (zh) * | 2021-02-04 | 2023-05-23 | 中国农业科学院兰州兽医研究所 | Hdac5基因敲除的bhk-21细胞系及其构建方法和应用 |
CN113248496B (zh) * | 2021-05-06 | 2022-02-11 | 东南大学 | 吡咯并吡啶类化合物及其盐及其用途 |
CN113666934B (zh) * | 2021-07-28 | 2023-06-23 | 北京深度制耀科技有限公司 | Cdk9激酶抑制剂 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
IL150388A0 (en) | 1999-12-24 | 2002-12-01 | Aventis Pharma Ltd | Azaindoles |
GB9930698D0 (en) * | 1999-12-24 | 2000-02-16 | Rhone Poulenc Rorer Ltd | Chemical compounds |
GB0115109D0 (en) | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
PL1737850T3 (pl) | 2004-04-19 | 2008-02-29 | Symed Labs Ltd | Nowy sposób wytwarzania linezolidu i związków pokrewnych |
WO2006008754A1 (en) | 2004-07-20 | 2006-01-26 | Symed Labs Limited | Novel intermediates for linezolid and related compounds |
BRPI0514094A (pt) | 2004-08-02 | 2008-05-27 | Osi Pharm Inc | composto, composição, e, método de tratamento de distúrbio hiperproliferativo |
US7511013B2 (en) | 2004-09-29 | 2009-03-31 | Amr Technology, Inc. | Cyclosporin analogues and their pharmaceutical uses |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
PL1962830T3 (pl) | 2005-12-23 | 2013-08-30 | Glaxosmithkline Llc | Azaindolowe inhibitory kinaz aurora |
DE602007011645D1 (de) * | 2006-09-22 | 2011-02-10 | Glaxo Group Ltd | Pyrroloä2, 3-büpyridin-4-yl-benzolsulfonamidverbindungen als ikk2-hemmer |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
WO2008049856A2 (en) | 2006-10-25 | 2008-05-02 | Ingenium Pharmaceuticals Gmbh | Methods of treating pain using cdk inhibitors |
CN101568530A (zh) * | 2006-12-22 | 2009-10-28 | 诺瓦提斯公司 | 吲哚-4-基-嘧啶-2-基胺衍生物及其作为细胞周期蛋白依赖性激酶抑制剂的用途 |
CN101616902B (zh) | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
US7998966B2 (en) | 2007-04-13 | 2011-08-16 | Supergen, Inc. | Axl kinase inhibitors |
BRPI0810362A2 (pt) | 2007-04-19 | 2014-10-29 | Concert Pharmaceuticals Inc | Compostos de morfolinila deuterados |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
JP2010540635A (ja) | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
CN101889004B (zh) | 2007-10-12 | 2014-09-10 | 阿斯利康公司 | 蛋白激酶抑制剂 |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
EP2212298B1 (en) | 2007-10-18 | 2013-03-27 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
WO2009055006A1 (en) | 2007-10-26 | 2009-04-30 | Concert Pharmaceuticals, Inc. | Deuterated darunavir |
US20090118276A1 (en) * | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
GB0804592D0 (en) * | 2008-03-12 | 2008-04-16 | Glaxo Group Ltd | Novel compounds |
WO2010003133A2 (en) * | 2008-07-03 | 2010-01-07 | Exelixis Inc. | Cdk modulators |
DK2331547T3 (da) | 2008-08-22 | 2014-11-03 | Novartis Ag | Pyrrolopyrimidinforbindelser som CDK-inhibitorer |
DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
CN104662018B (zh) * | 2012-04-20 | 2017-10-24 | 阿迪维纳斯治疗有限公司 | 取代的杂双环化合物、组合物及其医疗应用 |
WO2013157021A1 (en) * | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
-
2014
- 2014-03-13 CA CA2905530A patent/CA2905530A1/en not_active Abandoned
- 2014-03-13 CA CA2905935A patent/CA2905935A1/en not_active Abandoned
- 2014-03-13 AR ARP140100937A patent/AR101528A1/es unknown
- 2014-03-13 BR BR112015023356A patent/BR112015023356A2/pt not_active IP Right Cessation
- 2014-03-13 MX MX2015012896A patent/MX2015012896A/es unknown
- 2014-03-13 US US14/780,018 patent/US9796708B2/en active Active
- 2014-03-13 JP JP2015561916A patent/JP2016514113A/ja active Pending
- 2014-03-13 JP JP2016501955A patent/JP2016516713A/ja active Pending
- 2014-03-13 AU AU2014234077A patent/AU2014234077A1/en not_active Abandoned
- 2014-03-13 MX MX2015012899A patent/MX2015012899A/es unknown
- 2014-03-13 BR BR112015023187A patent/BR112015023187A2/pt not_active IP Right Cessation
- 2014-03-13 EP EP14765781.1A patent/EP2970278A4/en not_active Withdrawn
- 2014-03-13 CN CN201480026524.6A patent/CN105324380A/zh active Pending
- 2014-03-13 AU AU2014231567A patent/AU2014231567A1/en not_active Abandoned
- 2014-03-13 CN CN201480026207.4A patent/CN105246890A/zh active Pending
- 2014-03-13 EP EP14715513.9A patent/EP2970264A1/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
AU2014234077A1 (en) | 2015-10-01 |
CA2905530A1 (en) | 2014-09-18 |
CN105324380A (zh) | 2016-02-10 |
AU2014231567A1 (en) | 2015-10-01 |
BR112015023356A2 (pt) | 2017-07-18 |
CN105246890A (zh) | 2016-01-13 |
CA2905935A1 (en) | 2014-09-25 |
AR101528A1 (es) | 2016-12-28 |
MX2015012899A (es) | 2016-06-02 |
JP2016516713A (ja) | 2016-06-09 |
EP2970264A1 (en) | 2016-01-20 |
US20160060257A1 (en) | 2016-03-03 |
EP2970278A4 (en) | 2016-12-07 |
JP2016514113A (ja) | 2016-05-19 |
MX2015012896A (es) | 2016-06-02 |
US9796708B2 (en) | 2017-10-24 |
EP2970278A1 (en) | 2016-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015023187A2 (pt) | inibidores de pirrolo[2,3 - b] piridina cdk9 kinase | |
BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
BR112017007662A8 (pt) | Composto, composição farmacêutica e uso de um composto | |
PH12016500024A1 (en) | Bromodomain inhibitor | |
SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
NI201500067A (es) | Compuestos de pirrolopirimidina como inhibidores de quinasa | |
NI201500059A (es) | Inhibidores de la tirosina-quinasa de bruton | |
UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
CO6680717A2 (es) | Derivados de quinolina y quinoxalina como inhibidores de cinasa | |
TR201810944T4 (tr) | Fgfr4 inhibitörleri olarak halka-füzyonlu bisiklik piridil türevleri. | |
CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
BR112015017997A8 (pt) | amidas de quinolina e quinoxalina como moduladores de canais de sódio, composição farmacêutica que as compreende e uso | |
BR112015018095A2 (pt) | moduladores de receptor nmda de espiro-lactama e usos dos mesmos | |
CR20130210A (es) | DERIVADOS DE IMIDAZO[1,2-b]PIRIDAZINA E IMIDAZO[4,5-B]PIRIDINA COMO INHIBIDORES DE JAK | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
BR112015023417A2 (pt) | compostos heterocíclicos e seus usos | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
BR112019001921A2 (pt) | moduladores do receptor nmda de espiro-lactama e seus usos | |
CR20140031A (es) | Derivados de piridin-2(1h)-ona como inhibidores de jak | |
BR112015023161A2 (pt) | derivados de piridin-4-ila | |
MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina | |
BR112017023147A2 (pt) | azabenzimidazóis e seu uso como moduladores do receptor de ampa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law | ||
B06F | Objections, documents and/or translations needed after an examination request according art. 34 industrial property law | ||
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 5A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2505 DE 08-01-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |